Table 3.

EORTC response as correlated with length of time on therapy, reason off study, RECIST 1.1 response, and CB ≥ 9 months.

EORTC PET response at week 8Patient numberLength of time on therapy (months)Reason off studyRECIST 1.1 response at week 8Best RECIST 1.1 responseCB ≥ 9 months
Not performed21.1CPDNANEN
71.6CPDSDSDN
11.9PDPDPDN
Progressive metabolic disease171.9PDPDPDN
142.8CPDSDSDN
126.9AESDSDN
610.7PDSDSDY
Stable metabolic disease51.9AESDSDN
33.6MDCSDSDN
95.6PDSDSDN
198.1PDSDSDN
158.6PDSDSDY
1010.3PDSDSDY
1310.5CPDSDSDY
811.2PDSDSDY
2114.9PDSDSDY
2016.7AESDSDY
1631.7SCSDSDY
Partial metabolic response47.2PDSDSDN
1111.3PDSDSDY
  • Abbreviations: AE, adverse event; CB, clinical benefit rate; CPD, clinical progressive disease; MDC, MD choice; NA, not applicable; NE, nonevaluable; SC, study closure.